eGFR Rate-of-Change Interpretation: What Your Trend Means for Your Health

What eGFR is, and what it is not

eGFR, or estimated glomerular filtration rate, is a calculated estimate of how well the kidneys filter blood, usually derived from serum creatinine (sometimes combined with cystatin C) using an equation such as CKD-EPI. It is reported in mL/min/1.73 m² and is an estimate, not a direct measurement of filtration, so a single result can be pulled up or down by hydration status, recent exercise, muscle mass, or acute illness.

A single eGFR value tells you where kidney function stands today. The rate of change across two or more measurements, taken at least 90 days apart, tells you where it is heading, and that trajectory is what most guideline bodies and clinicians use to decide whether a given number needs action. Widely used clinical definitions treat a sustained loss greater than 5 mL/min/1.73 m² per year, or a confirmed drop of 25% or more within any 12-month window, as rapid progression warranting evaluation, while a decline of roughly 1 mL/min/1.73 m² per year or less is broadly consistent with expected aging after mid-life. The exact numeric thresholds below are commonly cited in nephrology and diabetes guidance; because specific guideline document versions were not independently verified for this draft, readers and clinicians should confirm current thresholds against the published KDIGO chronic kidney disease guideline and current FDA drug labels before making a dosing decision.

The useful question for most readers is not "is my eGFR normal" but "is my eGFR stable." A value of 65 that has held steady for three years carries different implications than a value of 65 that was 85 two years ago.

Is one eGFR reading enough to know your trend?

No. Intra-individual variability in creatinine-based eGFR is real: dehydration, a high-protein meal, intense exercise the day before a blood draw, or an intercurrent illness can shift a result by several mL/min/1.73 m² without reflecting any change in true kidney function. Because of this noise, a CKD diagnosis and any meaningful discussion of "rate of change" require at least two eGFR measurements taken 90 or more days apart. Three or more values, allowing a simple regression line rather than a two-point slope, are more resistant to a single outlier result.

What counts as normal, and what is the longevity-medicine target?

Standard clinical staging (used across nephrology practice for over a decade and reaffirmed in recent KDIGO guidance) classifies kidney function as follows:

An eGFR of 65 in a 25-year-old is a different clinical situation than an eGFR of 65 in a 78-year-old, and staging alone does not capture that. Some longevity-focused clinicians treat eGFR in the 75-89 range as worth watching even though it falls short of a formal CKD stage, reasoning that filtration capacity generally trends downward with age and that a value in this range combined with any downward slope deserves earlier attention than the staging table alone implies. This is a clinical judgment applied by some practices rather than a formal diagnostic category, and it should not be read as an established mortality threshold; large cohort studies have reported that cardiovascular risk begins rising at eGFR levels somewhat above the traditional 60 cutoff, but the precise hazard ratios require verification against the primary publication before being cited as fact.

Structural kidney disease can also exist with a normal eGFR. A urine albumin-to-creatinine ratio (UACR) above 30 mg/g, in the presence of a normal filtration rate, still meets the definition of CKD stage G1 with albuminuria, and albuminuria meaningfully changes prognosis and monitoring frequency regardless of the eGFR number itself.

How to calculate your own rate of change

The calculation is simple arithmetic once you have two dated, confirmed results:

Rate of change = (later eGFR − earlier eGFR) ÷ years between the two tests

Example: eGFR 82 in January 2023 and eGFR 74 in January 2025 gives a rate of roughly minus 4 mL/min/1.73 m² per year. Both values sit in the "mildly decreased" G2 category on their own, but the slope is already in the range most guidance treats as moderate decline warranting closer follow-up and repeat testing sooner than the routine annual interval.

Do not calculate a meaningful trend from two results drawn less than 90 days apart, and do not calculate one from results obtained under very different hydration, illness, or exercise conditions without accounting for that context.

Does kidney function change how metformin, GLP-1 drugs, SGLT2 inhibitors, or TRT should be dosed?

Kidney function is directly relevant to several medications common in metabolic and hormone care. The evidence tier differs by drug, and readers should not use this section for individual dosing decisions; it is intended to explain why a clinician asks for an updated eGFR before renewing or adjusting these medications.

Metformin. Current FDA labeling for metformin identifies eGFR as the key safety parameter because of lactic acidosis risk in reduced kidney function. Commonly cited thresholds are continued use with monitoring above eGFR 45, dose reduction and closer monitoring in the 30-44 range, and discontinuation below eGFR 30. This is an FDA-labeled, guideline-reinforced threshold, but the exact current wording should be checked against the manufacturer's current prescribing information, since labels are periodically revised.

GLP-1 receptor agonists (semaglutide and similar agents). Labeling for semaglutide has generally not required dose adjustment for reduced kidney function until eGFR falls to a very low level or dialysis begins, which is a materially different risk profile than metformin. Separately, large randomized cardiovascular and kidney outcome trials in people with type 2 diabetes and chronic kidney disease have reported that GLP-1 receptor agonist and SGLT2 inhibitor therapy reduced major kidney disease events compared with placebo. This is trial-level evidence in a specific population (people with type 2 diabetes and established CKD), not a general claim that these drugs improve kidney function in everyone who takes them, and the exact effect sizes reported by any individual trial should be verified against the published paper before being quoted to a patient.

SGLT2 inhibitors. These drugs typically cause a small, expected initial dip in eGFR (often described in trials as roughly 3-5 mL/min/1.73 m²) at the start of treatment, followed by a slower rate of long-term decline than placebo in trial populations with CKD; this early dip is generally considered part of the drug's mechanism rather than a sign of harm, but any larger or sustained drop should prompt reassessment. Initiation and continuation thresholds vary by specific agent and are outlined in each drug's FDA label.

Testosterone replacement therapy. TRT itself does not have an eGFR-based dosing threshold in its labeling. However, advanced CKD is associated with altered sex-hormone binding globulin and anemia of chronic kidney disease, both of which complicate the interpretation of free testosterone and hematocrit results. In practice, a clinician managing TRT in a patient with reduced eGFR should review the full kidney picture, including anemia workup, before adjusting dose based on hematocrit alone. This is site and clinical judgment rather than a labeled requirement.

What causes a faster-than-expected decline?

A confirmed decline steeper than the "moderate" range should prompt a search for a cause rather than being treated as background noise. Commonly implicated factors include:

• Poorly controlled diabetes, where sustained hyperglycemia damages the glomerular filtration barrier over years.
• Uncontrolled hypertension, which accelerates nephrosclerosis; blood pressure control is one of the few interventions with strong trial support for slowing progression.
• Regular NSAID use, which can reduce renal blood flow through prostaglandin inhibition and cause a real, sometimes reversible, drop in filtration.
• Recent iodinated contrast exposure, particularly in patients with a baseline eGFR below 45, where imaging societies recommend pre-procedure risk assessment (see the American College of Radiology's contrast guidance below).
• Volume depletion, obstruction, or an acute illness, which can look identical to true CKD progression on a single lab result and needs to be ruled out before assuming permanent decline.

Specific relative-risk figures for these associations (for example, exact fold-increases in acute kidney injury with NSAID use) vary across studies and were not independently verified for this draft; treat any single precise number in older sources with caution and confirm it against a current systematic review if it will inform a clinical decision.

How often should eGFR be rechecked?

Monitoring frequency should scale with both the absolute value and the trend:

• Stable, eGFR 90 or above, no albuminuria: annual eGFR and UACR if diabetes or hypertension are present; every one to two years otherwise as part of routine metabolic screening.
• eGFR 45-89, or a documented decline of roughly 2-5 mL/min/1.73 m² per year: recheck every three to six months to confirm whether the trend is real and continuing.
• eGFR below 30, or a confirmed rapid decline: recheck at least every three months, with nephrology involvement, and sooner if symptoms change.

When is nephrology referral appropriate?

Reasonable, widely used triggers for referral include an eGFR confirmed below 30 on two occasions at least 90 days apart, a confirmed decline of 25% or more within 12 months, a UACR persistently above 300 mg/g, unexplained blood in the urine combined with any reduction in eGFR, and hypertension that resists treatment while kidney function is falling. Earlier referral generally allows more time for cause-specific treatment and, where relevant, transplant planning, compared with referral made only after kidney failure is already established. Anyone with a very low eGFR, new significant swelling, shortness of breath, confusion, or a sharply reduced urine output should seek urgent medical care rather than waiting for a scheduled follow-up.

What is established, what is plausible, and what is not established

Established: the CKD staging framework based on eGFR thresholds; the requirement for two measurements 90 or more days apart to confirm a trend or diagnosis; metformin's eGFR-based dosing caution built into its FDA label; the existence of large outcome trials showing kidney-protective effects of SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes and CKD.

Plausible but not fully established for a general population: treating an eGFR in the mid-70s to high-80s as an early warning sign in people without diabetes, hypertension, or albuminuria; using GLP-1 or SGLT2 drugs specifically for kidney protection in people who do not have diabetes or already-diagnosed CKD, outside the populations actually studied.

Not established from the material available here: precise relative-risk multipliers for NSAID-associated kidney injury, exact hazard ratios for mortality at specific eGFR bands, and any claim that a specific over-the-counter supplement or diet reliably reverses an established downward eGFR trend. These require verification against the current primary literature before being used in patient-facing decisions.

A decision framework for reading your own eGFR trend

Use this to decide what your next step should be, not to replace a clinician's assessment.

Step 1: Do you have two dated results at least 90 days apart? If not, your current number is a snapshot, not a trend. Get a repeat test rather than reacting to a single value, unless the value itself is very low (below 30) or you have new symptoms.

Step 2: Calculate the slope. (Later result − earlier result) ÷ years between tests.

Step 3: Check whether albuminuria changes the picture. A rising or elevated UACR alongside any of the above raises the urgency by roughly one tier. A stable eGFR with new albuminuria is not reassuring on its own.

Step 4: Reconcile with medications. Before assuming a drop is disease progression, review recent NSAID use, new blood pressure medications, dehydration, recent contrast imaging, and any new supplement. A medication-related dip is sometimes reversible; a disease-driven decline usually is not.

Step 5: Decide the right conversation, not the right number. The goal of tracking rate of change is to know when to escalate a conversation with a clinician (sooner testing, medication review, or referral) rather than to self-diagnose kidney disease from a single lab value.

Common questions